**Principal Investigator**
Peter J. Snyder

**Study Title:**
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands

**Purpose:**
To test the safety and efficacy of paltusotine, an oral medication, for the treatment of acromegaly.

**Brief Description**
Paltusotine will be taken orally once a day, and its effect on the clinical manifestations and blood levels of IGF-1 will be evaluated every four weeks. The initial study lasts 48 weeks, and an optional extension lasts 96 weeks.

**Eligibility**
Men and women who are 18-80 years of age who have been diagnosed as having acromegaly and are currently being treated with long-acting somatostatin receptor ligands (lanreotide or octreotide).

**Compensation (if applicable)**
Subjects will receive compensation to cover travel and parking

**Which section would you like the trial listed under?**
Pituitary Center Trials

**Name**
Eileen Markmann

**Phone**
(215) 898-5664

**Email:**
markmann@pennmedicine.upenn.edu